CTMC 2021 Webinar Series: Ethical Issues in Acute and Chronic Neurological Conditions

Michael Linke, Ph.D.
Adjunct Professor, Dept. of Internal Medicine
Chair, University of Cincinnati Institutional Review Board
Chair StrokeNet Central IRB
linkemj@uc.edu
• This update to the American Academy of Neurology’s 1998 position statement endeavors to provide guidance for the consistent ethical conduct and review of neurologic research involving human participants.
7 principles for the ethical analysis of research on human participants

- social value
- scientific validity
- fair participant selection
- favorable risk–benefit ratio
- independent review
- informed consent
- respect for participants

Addressing all 7 principles is necessary and sufficient for clinical research to be considered ethically permissible.
<table>
<thead>
<tr>
<th>Requirement</th>
<th>Summary</th>
<th>Examples of violations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Social value</td>
<td>A study must have the potential to improve human health or meaningfully increase society’s knowledge of human biology</td>
<td>A placebo-controlled trial of a “me-too” medication, i.e., no safer, more effective, or cheaper than existing medications for the same illness</td>
</tr>
<tr>
<td>Requirement</td>
<td>Summary</td>
<td>Examples of violations</td>
</tr>
<tr>
<td>--------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Social value</td>
<td>A study must have the potential to improve human health or meaningfully increase society’s knowledge of human biology</td>
<td>A placebo-controlled trial of a “me-too” medication, i.e., no safer, more effective, or cheaper than existing medications for the same illness</td>
</tr>
<tr>
<td>Scientific validity</td>
<td>A study must use accepted scientific methodology to produce valid and reproducible results</td>
<td>A study that uses unblinded and biased assessments of outcomes that systematically favor the study drug</td>
</tr>
<tr>
<td>Requirement</td>
<td>Summary</td>
<td>Examples of violations</td>
</tr>
<tr>
<td>---------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Social value</td>
<td>A study must have the potential to improve human health or meaningfully increase society's knowledge of human biology</td>
<td>A placebo-controlled trial of a “me-too” medication, i.e., no safer, more effective, or cheaper than existing medications for the same illness</td>
</tr>
<tr>
<td>Scientific validity</td>
<td>A study must use accepted scientific methodology to produce valid and reproducible results</td>
<td>A study that uses unblinded and biased assessments of outcomes that systematically favor the study drug</td>
</tr>
<tr>
<td>Fair participant selection</td>
<td>Study sites, populations, and participants must be selected based primarily on scientific criteria and vulnerable populations must not be targeted or excluded in clinical studies</td>
<td>A study that excludes female participants without an explicit and valid scientific rationale</td>
</tr>
<tr>
<td>Requirement</td>
<td>Summary</td>
<td>Examples of violations</td>
</tr>
<tr>
<td>----------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Social value</td>
<td>A study must have the potential to improve human health or meaningfully increase society's knowledge of human biology</td>
<td>A placebo-controlled trial of a “me-too” medication, i.e., no safer, more effective, or cheaper than existing medications for the same illness</td>
</tr>
<tr>
<td>Scientific validity</td>
<td>A study must use accepted scientific methodology to produce valid and reproducible results</td>
<td>A study that uses unblinded and biased assessments of outcomes that systematically favor the study drug</td>
</tr>
<tr>
<td>Fair participant selection</td>
<td>Study sites, populations, and participants must be selected based primarily on scientific criteria and vulnerable populations must not be targeted or excluded in clinical studies</td>
<td>A study that excludes female participants without an explicit and valid scientific rationale</td>
</tr>
<tr>
<td>Favorable risk-benefit ratio</td>
<td>Risks to participants must be minimized and potential benefits to participants and society must exceed the risks</td>
<td>A trial using a placebo control even though safe and effective treatments are otherwise readily available to participants</td>
</tr>
<tr>
<td>Requirement</td>
<td>Summary</td>
<td>Examples of violations</td>
</tr>
<tr>
<td>---------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Social value</td>
<td>A study must have the potential to improve human health or meaningfully increase society's knowledge of human biology</td>
<td>A placebo-controlled trial of a “me-too” medication, i.e., no safer, more effective, or cheaper than existing medications for the same illness</td>
</tr>
<tr>
<td>Scientific validity</td>
<td>A study must use accepted scientific methodology to produce valid and reproducible results</td>
<td>A study that uses unblinded and biased assessments of outcomes that systematically favor the study drug</td>
</tr>
<tr>
<td>Fair participant selection</td>
<td>Study sites, populations, and participants must be selected based primarily on scientific criteria and vulnerable populations must not be targeted or excluded in clinical studies</td>
<td>A study that excludes female participants without an explicit and valid scientific rationale</td>
</tr>
<tr>
<td>Favorable risk–benefit ratio</td>
<td>Risks to participants must be minimized and potential benefits to participants and society must exceed the risks</td>
<td>A trial using a placebo control even though safe and effective treatments are otherwise readily available to participants</td>
</tr>
<tr>
<td>Independent review</td>
<td>Clinical studies must be reviewed and approved by knowledgeable individuals unaffiliated with the research</td>
<td>A study conducted in a nation or institution where institutional review board review is pro forma, with guaranteed approval</td>
</tr>
<tr>
<td>Requirement</td>
<td>Summary</td>
<td>Examples of violations</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Social value</td>
<td>A study must have the potential to improve human health or meaningfully increase society’s knowledge of human biology</td>
<td>A placebo-controlled trial of a “me-too” medication, i.e., no safer, more effective, or cheaper than existing medications for the same illness</td>
</tr>
<tr>
<td>Scientific validity</td>
<td>A study must use accepted scientific methodology to produce valid and reproducible results</td>
<td>A study that uses unblinded and biased assessments of outcomes that systematically favor the study drug</td>
</tr>
<tr>
<td>Fair participant selection</td>
<td>Study sites, populations, and participants must be selected based primarily on scientific criteria and vulnerable populations must not be targeted or excluded in clinical studies</td>
<td>A study that excludes female participants without an explicit and valid scientific rationale</td>
</tr>
<tr>
<td>Favorable risk–benefit ratio</td>
<td>Risks to participants must be minimized and potential benefits to participants and society must exceed the risks</td>
<td>A trial using a placebo control even though safe and effective treatments are otherwise readily available to participants</td>
</tr>
<tr>
<td>Independent review</td>
<td>Clinical studies must be reviewed and approved by knowledgeable individuals unaffiliated with the research</td>
<td>A study conducted in a nation or institution where institutional review board review is pro forma, with guaranteed approval</td>
</tr>
<tr>
<td>Informed consent</td>
<td>Participants must be accurately informed of and understand the purpose, risks, benefits, and alternatives of a clinical study, and make an uncoerced decision whether or not to participate</td>
<td>A study in which participants are not informed of existing effective treatments outside the study</td>
</tr>
<tr>
<td>Requirement</td>
<td>Summary</td>
<td>Examples of violations</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Social value</td>
<td>A study must have the potential to improve human health or meaningfully increase society’s knowledge of human biology</td>
<td>A placebo-controlled trial of a “me-too” medication, i.e., no safer, more effective, or cheaper than existing medications for the same illness</td>
</tr>
<tr>
<td>Scientific validity</td>
<td>A study must use accepted scientific methodology to produce valid and reproducible results</td>
<td>A study that uses unblinded and biased assessments of outcomes that systematically favor the study drug</td>
</tr>
<tr>
<td>Fair participant selection</td>
<td>Study sites, populations, and participants must be selected based primarily on scientific criteria and vulnerable populations must not be targeted or excluded in clinical studies</td>
<td>A study that excludes female participants without an explicit and valid scientific rationale</td>
</tr>
<tr>
<td>Favorable risk–benefit ratio</td>
<td>Risks to participants must be minimized and potential benefits to participants and society must exceed the risks</td>
<td>A trial using a placebo control even though safe and effective treatments are otherwise readily available to participants</td>
</tr>
<tr>
<td>Independent review</td>
<td>Clinical studies must be reviewed and approved by knowledgeable individuals unaffiliated with the research</td>
<td>A study conducted in a nation or institution where institutional review board review is pro forma, with guaranteed approval</td>
</tr>
<tr>
<td>Informed consent</td>
<td>Participants must be accurately informed of and understand the purpose, risks, benefits, and alternatives of a clinical study, and make an uncoerced decision whether or not to participate</td>
<td>A study in which participants are not informed of existing effective treatments outside the study</td>
</tr>
<tr>
<td>Respect for enrolled and potential participants</td>
<td>Potential and enrolled participants must be treated respectfully, with attention to and protection of their privacy and interests throughout the course of the study</td>
<td>A study of a genetic test in which identifiable results can be obtained by employers, law enforcement, or others</td>
</tr>
</tbody>
</table>
Historical concerns

• IRB review
• Equitable research participant inclusion
• Cognitive impairment in research participants
IRB review

• simplifying review of multisite studies under central IRBs
• reducing review of low-risk studies
• giving research participants options for broad consent to future studies
• supports IRBs’ use of publicly available ethics checklists
• encourages mechanisms to allow appeals when IRB rulings conflict with the views of independent reviewers
Equitable research participant inclusion

- include both sexes and minority races and ethnicities
- include individuals of all ages
- include enough participants to allow for a valid analysis of whether women or minority participants are affected differently than other participants
- NIH funded trials submit these subgroup analyses to ClinicalTrials.gov
- where possible, participant recruitment should take place at community hospitals as well as academic centers, to promote geographic and socioeconomic diversity
Cognitive impairment in research participants

- temporary or permanent cognitive impairment
- impaired or nonexistent capacity to engage in the informed consent process
- capacity may fluctuate over time
- capacity screening instruments should be used
- results must be confirmed by a qualified clinician
Cognitive impairment in research participants

- The principle of informed consent requires the provision of accurate information about the purpose, methods, risks, benefits, and alternatives to the study and an uncoerced decision by a participant with decision-making capacity.
Cognitive impairment in research participants

Decisional capacity includes 4 abilities:
(1) understanding
(2) appreciation
(3) reasoning
(4) the expression of choice
Importantly, decisional capacity is recognized to exist on a continuum, depending on the complexity and importance of a decision, and not to be a dichotomous all-or-nothing characteristic.
• Legally Authorized Representatives (LARs)
• Common Rule specifies that, where state law does not specify rules for surrogate decision-making about research, surrogates for medical decision-making can also be considered surrogates for decisions about clinical research.
Cognitive impairment in research participants

An example of the order of a recognized hierarchy

1) The health care agent, upon proper invocation of the health care proxy
2) Legally appointed guardian or conservator
3) Spouse
4) Adult children – (majority consensus encouraged)
5) The subject’s parent – (consensus encouraged)
6) Adult siblings – (majority consensus encouraged).
Cognitive impairment in research participants

Surrogate Consent

The surrogate should use a substituted judgment standard, making the decision based on the participant’s historical beliefs and values, as the surrogate believes the participant would, were the participant able to undertake the informed consent process.
Surrogate Consent

IRBs may require additional safeguards, such as independent consent monitors, depending on the degree of cognitive incapacity and the study’s risk–benefit ratio and complexity.

In developing such safeguards, IRBs should make every effort to fully protect participants with dementia and other cognitive impairments, while minimizing impediments to studies of these important conditions.
Conducting emergency research without prospective informed consent
Exception from Informed Consent (EFIC)

Planned Emergency Research
Planned Emergency Research subject to HHS regulations 45CFR46 may also be approved with an exception to informed consent per letter number 97-01 from OPRR dated Oct 31, 1996.
Conditions for study to be eligible for EFIC

1. Life-threatening situation that necessitates urgent intervention
2. Available treatments are unproven or unsatisfactory
3. Collection of valid scientific evidence is necessary to determine the safety and effectiveness of the intervention
4. Obtaining informed consent is not feasible
5. The intervention must be administered before consent can be obtained from the subject's legally authorized representative.
6. No reasonable way to prospectively identify potential participants
7. Participation holds out the prospect of direct benefit to the subjects
8. Could not practicably be carried out without the waiver
Consent Requirements

50.24(a)(5)—Investigator must commit to attempting to get consent from subject’s LAR during the potential therapeutic window before initiating intervention without consent; these contact efforts must be summarized for the IRB at continuing review. [paraphrased]

50.24(a)(6) & (7)(v)—If LAR is not available, the investigator must also commit to attempting to contacting a family member to ask if they object to the subject’s participation; these efforts likewise must be summarized for the IRB. [paraphrased]
Consent Requirements

50.24(b)—Process must be in place to consent the subject, their LAR, or a family member at the earliest feasible opportunity. [paraphrased]

50.24(b)—Subject, their LAR, or a family member at the point of being told of the study may discontinue the subject’s participation. [paraphrased]

50.24(b)—If it was the LAR or family member who was provided the after- intervention consent discussion; when the subject regains capacity they must be informed of the research and given their own opportunity to consent. [paraphrased]
50.24(a)(7)—Community Consultation

56.109(g)—Public Disclosure
Another Mechanism for waiver of informed consent.
• expanded waiving informed consent when there is minimal risk to participants to FDA-regulated studies

• Current FDA regulations only allowed for exceptions from informed consent requirements in life-threatening situations or for emergency research.

• FDA says it plans to revise its regulations on informed consent to allow for waivers or alterations for minimal risk clinical investigations.
FDA says it does not intend to object to an IRB waiving the requirement to obtain informed consent when the IRB finds:

• The clinical investigation involves no more than minimal;
• The waiver or alternation will not adversely affect the rights and welfare of the subjects;
• The clinical investigation could not practicably be carried out without the waiver or alternation; and
• Whenever appropriate, the subjects will be provided with additional pertinent information after participation.
FDA says it considers risk to be minimal when

• "the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance or routine physical or psychological examinations or tests."
Participation in a randomized, controlled trial may pose no more than minimal risk when:

1) genuine clinical equipoise exists;
2) all of the treatment options included in the research study fall within the current standard of care;
3) there is no currently available treatment with a more favorable risk-benefit profile than the treatments included in the study;
4) the nontherapeutic components of the research are safely under the minimal risk threshold; and
5) the research protocol provides sufficient latitude for treating physicians to individualize care when appropriate.
Questions/Discussion
Contact Information

Mike Linke
linkemj@uc.edu
513-558-2599